

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Original) A denatured collagen type-IV selective peptide antagonist.
2. (Currently amended) A denatured collagen type-IV selective peptide antagonist according to Claim 1 comprising a core amino acid sequence L-K-Q-N-G-G-N-F-S-L.
3. (Original) The antagonist of claim 2 wherein the antagonist is a peptide comprising an amino acid sequence  $\text{NH}_2\text{-C-L-K-Q-N-G-G-N-F-S-L-G-COOH-}$ .
4. (Original) The antagonist of claim 2 wherein the antagonist is a peptide comprising an amino acid sequence  $\text{NH}_2\text{-S-L-K-Q-N-G-G-N-F-S-L-C-COOH}$ .
5. (Original) The antagonist of claim 2 wherein the antagonist is a peptide consisting of an amino acid sequence  $\text{NH}_2\text{-K-G-G-C-L-K-Q-N-G-G-N-F-S-L-G-G-K-A-COOH}$ .
6. (Original) The antagonist of claim 2 wherein the binding affinity of the denatured collagen type-IV selective antagonist to denatured type-IV collagen is substantially greater than the binding affinity of said antagonist to native collagen type-IV.
7. (Original) The antagonist of claim 2 wherein the binding affinity of the selective denatured collagen type-IV antagonist to denatured type-IV collagen is 100-fold greater than the binding affinity of said antagonist to native collagen.
8. (Original) The antagonist of claim 2 wherein the selective denatured collagen type-IV antagonist inhibits cellular interaction with denatured collagen type-IV.
9. (Currently amended) A pharmaceutical composition comprising a selective denatured collagen type-IV antagonist according to Claim 1 and a pharmaceutically acceptable excipient.
10. (Original) The pharmaceutical composition of claim 9 wherein the composition comprises a cytotoxic agent.
11. (Original) The pharmaceutical composition of claim 9 wherein the composition comprises a radioactive material.
12. (Original) The pharmaceutical composition of claim 9 wherein the composition comprises a cytostatic agent.

13. (Currently amended) A method for inhibiting angiogenesis in a patient comprising:  
administering an angiogenesis-inhibiting effective amount of a denatured collagen type-IV selective antagonist according to Claim 1 to the patient.
14. (Currently amended) A method of detecting angiogenesis in a patient comprising:  
administering a denatured collagen type-IV selective antagonist according to Claim 1 to the patient, and detecting bound selective denatured collagen type-IV antagonist in the patient.
15. (Currently amended) A method of treating a tumor in a patient comprising:  
administering an angiogenesis-inhibiting effective amount of a denatured collagen type-IV selective antagonist according to Claim 1 to the patient.
16. (Currently amended) A method of treating metastases in a patient comprising:  
administering an angiogenesis-inhibiting effective amount of a denatured collagen type-IV selective antagonist according to Claim 1 to the patient.
17. (Currently amended) A method of treating angiogenic disease in a patient comprising:  
administering an angiogenesis-inhibiting effective amount of a denatured collagen type-IV selective antagonist according to Claim 1 to the patient.
18. (Original) The method of claim 13 wherein the denatured collagen type-IV selective antagonist is administered:  
intravenously, intraperitoneally, intramuscularly, subcutaneously, intracavity, transdermally, topically, intraocularly, orally, intranasally, or by peristaltic means.
19. (Original) The method of claim 13 wherein the denatured collagen type-IV selective antagonist dose range is 0.1 milligram per kilogram per day to 300 milligrams per kilogram.
20. (Original) The method of claim 13 wherein the denatured collagen type-IV selective antagonist dose range is 10 milligrams to 3000 milligrams.
21. (Original) The method of claim 13 wherein the denatured collagen type-IV selective antagonist is administered in combination with a chemotherapeutic agent.
22. (Original) The method of claim 13 wherein the denatured collagen type-IV selective antagonist is administered in combination with a radioactive material.
23. (Original) The method of claim 13 wherein the denatured collagen type-IV selective antagonist is administered in conjunction with a cytostatic agent.
24. (Original) The method of claim 13 wherein the patient is a mammal.

25. (Original) The method of claim 13 wherein the patient is a human.
26. (Currently amended) A method for inhibiting tumor cell adhesion in a patient comprising:  
administering a tumor cell adhesion-inhibiting effective amount of a denatured collagen type-IV selective antagonist according to Claim 1 to the patient.
27. (Currently amended) A method of detecting tumor cell adhesion in a patient comprising:  
administering a denatured collagen type-IV selective antagonist according to Claim 1 to the patient, and detecting bound denatured collagen type-IV selective antagonist in the patient.
28. (Currently amended) A method of treating a tumor in a patient comprising:  
administering a tumor cell adhesion-inhibiting effective amount of a denatured collagen type-IV selective antagonist according to Claim 1 to the patient.
29. (Currently amended) A method of treating metastasis in a patient comprising:  
administering a tumor cell adhesion-inhibiting effective amount of a denatured collagen type-IV selective antagonist according to Claim 1 to the patient.
30. (Original) The method of claim 26 wherein the denatured collagen type-IV selective antagonist is administered:  
intravenously, intraperitoneally, intramuscularly, subcutaneously, intracavity, transdermally, topically, intraocularly, orally, intranasally, or by peristaltic means.
31. (Original) The method of claim 26 wherein the denatured collagen type-IV selective antagonist dose range is 0.1 milligram per kilogram per day to 300 milligrams per kilogram per day.
32. (Original) The method of claim 26 wherein the denatured collagen type-IV selective antagonist dose range is 10 milligrams to 3000 milligrams.
33. (Original) The method of claim 26 wherein the denatured collagen type-IV selective antagonist is administered in combination with a chemotherapeutic agent.
34. (Original) The method of claim 26 wherein the denatured collagen type-IV selective antagonist is administered in combination with a radioactive material.
35. (Original) The method of claim 26 wherein the denatured collagen type-IV selective antagonist is administered in conjunction with a cytostatic agent.
36. (Original) The method of claim 26 wherein the patient is a mammal.

37. (Original) The method of claim 26 wherein the patient is a human.